TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01450696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
Study: NCT01078909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Description: Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Description: Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
Study: NCT02417376

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: piezoelectric ultrasonic scaler (frequency of 28-36 KHz)
Description: Periodontal treatment in the form of scaling and root planing (SRP) is provided to the patients assigned to the experimental group, after baseline examination. Scaling is performed using piezoelectric ultrasonic scaler (frequency of 28-36 KHz) and root planing is performed using area specific Gracey curettes (set of 7 instruments number #1-14). SRP is completed in two appointments of 45 min to 1 hour, within 24 hours period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gracey curettes
Description: set of 7 instruments number #1-14
Study: NCT01450696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Study: NCT01121848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXALIPLATIN
Description: Pharmaceutical form: Lyophilized powder for injection (50 mg/vial or 100 mg/vial) or aqueous solution (50 mg/10 mL and 100 mg/20 mL) Route of administration: IV~Dose regimen:

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Pharmaceutical form: vials of 5 g/100mL Route of administration: IV~Dose regimen:

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Pharmaceutical form: vials of 5 g/100mL Route of administration: IV~Dose regimen:
Study: NCT05258448

Intervention type: OTHER
Intervention: Chemoradiotherapy
Description: Cardiac Magnetic Resonance scan and ECG
Study: NCT01450696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Study: NCT03070639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Sleep Intervention
Description: A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on the baby's sleep practices. Participant will also receive a free pack'n play, sleep sack, and educational resources on safe sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Scald Prevention Intervention
Description: A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on practices regarding scald risks in the home. Participant will also receive a bath thermometer, candy/frying thermometer, and educational resources on scald prevention.
Study: NCT01697423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet-rich plasma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: durolane
Study: NCT02147210

Intervention type: OTHER
Intervention: biological analysis
Study: NCT01167101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebamipide
Description: Rebamipide 100mg Tid for 28days
Study: NCT01167101

Intervention type: DRUG
Group type: OTHER
Intervention: pantoprazole
Description: pantoprazole 40mg qd for 28days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Description: pantoprazole 40mg qd for 28days
Study: NCT03780907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: 2 mg of E2007 was administered by mouth once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily of oral tablet formulation to be taken in the morning, one hour before breakfast, with a glass of water.
Study: NCT05036551

Intervention type: DIAGNOSTIC_TEST
Intervention: Kellgren Lawrence classification
Description: The Kellgren Lawrence classification was used in the radiological evaluation. It is a classification method used in the staging of knee osteoarthritis. Five stages were defined according to the anteroposterior X-ray.(Stage 0-5)

Intervention type: DIAGNOSTIC_TEST
Intervention: Kellgren Lawrence classification
Description: The Kellgren Lawrence classification was used in the radiological evaluation. It is a classification method used in the staging of knee osteoarthritis. Five stages were defined according to the anteroposterior X-ray.(Stage 0-5)
Study: NCT02394704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory attention training
Description: Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible while ruminating. Stimuli will consist of vibration via a wearable subwoofer or non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2 electrodes placed on the back near the shoulders) or vibratory stimulation with a vibroacoustic element placed on the back near the shoulders. Up to four sessions will be approximately 45 minutes, over the course of two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensory attention training
Description: Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible while ruminating. Stimuli will consist of vibration via a wearable subwoofer or non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2 electrodes placed on the back near the shoulders) or vibratory stimulation with a vibroacoustic element placed on the back near the shoulders. Up to four sessions will be approximately 45 minutes, over the course of two weeks.
Study: NCT01336452

Intervention type: RADIATION
Group type: OTHER
Intervention: DCE MRI
Description: DCE (dynamic contrast enhanced) MRI will be obtained just before CCRTx and immediately after finishing CCRTx with 0.1mmol/kg of MR contrast media; CEUS will be obtained just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx with 2.4 mL of SonoVue. Blood sampling for biomarker analysis will be performed just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx (20mL)
Study: NCT03968978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab (APFS)
Description: Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab (AI)
Description: Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
Study: NCT00991705

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan
Study: NCT02045589

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VCN-01
Description: Genetically modified human adenovirus encoding human PH20 hyaluronidase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane®
Description: 125 mg/m2 intravenous administration
Study: NCT01659775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sancuso patch
Description: Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24hours) prior to start of chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran inj.+Zofran tab.
Description: Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Active Comparator arm: administered intravenously (24mg or 32mg) on Day 1 of chemotherapy and orally (8mg bid) on Day 2-5.
Study: NCT02144051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5312
Description: AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the purpose of specifically suppressing human Androgen Receptor (AR) expression, thereby providing potential therapeutic benefit for the treatment of mCRPC and other AR-dependent cancers.
Study: NCT00260494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: standardized acupuncture intended to improve blood flow and reduce edema to lower extremity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: standardized sham acupuncture at same sites as acupuncture.
Study: NCT01325415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 25 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 25 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet
Study: NCT03723759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster Aspart 200 U/mL
Description: A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster Aspart 200 U/mL
Description: A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster Aspart 200 U/mL
Description: A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster Aspart 200 U/mL
Description: A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster Aspart 200 U/mL
Description: A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster Aspart 200 U/mL
Description: A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster aspart 100 U/mL
Description: A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster aspart 100 U/mL
Description: A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster aspart 100 U/mL
Description: A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.
Study: NCT02728336

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac MRI
Study: NCT01961557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EA-KAFO
Description: This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
Study: NCT03723759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster aspart 100 U/mL
Description: A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster aspart 100 U/mL
Description: A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster aspart 100 U/mL
Description: A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.
Study: NCT03224572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose vitamin C 30gm
Description: High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 500ml normal saline, once per week, and total 4-week treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal saline
Description: 500ml normal saline, once per week, and total 4-week treatment
Study: NCT04362787

Intervention type: DEVICE
Intervention: High pressure non invasive ventilation in acute hypercapnic respiratory failure
Description: Usage of High pressure non invasive ventilation in acute hypercapnic respiratory failure
Study: NCT04445324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional Online Peer Support Group (n=20)
Description: Trained Peer Support Workers (PSWs) from the Quebec Association of PSWs will organize and facilitate two series (one per condition) of 10 co-learning recovery workshops in a manner to simulate a typical peer support group. The difference of these transitional peer support groups to real community-based peer support groups is that (A) they will be facilitated by trained PSW, (B) they will have a personal-civic recovery focus, and (C) they will have a fixed, predetermined duration (10 weekly 60 to 90-minute online workshops). Typical Peer support groups bring together people who have similar concerns so they can explore solutions to overcome shared challenges and feel supported by others with similar experiences and who may better understand each other's situation. Peer support groups should ideally be independent from mental health and social services, although some services may facilitate and encourage the creation of (transitional) peer support groups, as is the case here. (WHO)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (pharmacotherapy and/or psychotherapy, n=10)
Description: When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group (pharmacotherapy and/or psychotherapy, n=10)
Description: When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
Study: NCT03290898

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training
Description: Training (HIIT)
Study: NCT02314416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic Stem Cells and Collagen Matrix
Description: Nucel will be applied in between two pieces of collagen matrix'. The NuCel-impregnated collagen matrix will be placed over a clean, debrided wound.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic Stem Cells and Collagen Matrix
Description: Nucel will be applied in between two pieces of collagen matrix'. The NuCel-impregnated collagen matrix will be placed over a clean, debrided wound.
Study: NCT00672867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: 30mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir dipivoxil
Description: 10mg
Study: NCT02090569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional micro-Doppler Sonography (fmDS)
Description: 1. Craniotomy according to MRI images~2. Dura opening~3. Sulcal Localization using neuronavigation~4. Functional micro-Doppler Sonography including morphologic (Bmode) and functional measurement of the cerebral blood volume dynamics at high spatio-temporal resolution (100µm-20ms) using high-frequency (15MHz) ultrasound. At least 5 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 15KHz and highpass filter of 10 to 70 Hz.~5. Exeresis of the dysplasic tissue~6. Control using fmDS before wound closure
Study: NCT02197845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: A specially trained (SCD knowledgable) Patient Navigator will act as a liaison who assists participants in increasing adherence to HU through disease education, addressing barriers to care and improving adherence to HU. PN utilize various techniques geared toward the individual patients needs. Interventions utilized by a PN include improving disease management skills, educational materials about disease, HU adherence, motivational interviewing, care coordination and social support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recruitment into Specialty Care
Description: A specially trained (SCD knowledgeable) Patient Navigator will act as a liaison to participants in increasing adherence to Hydroxyurea. Interventions utilized by a PN include teaching disease management skills, addressing barriers to care, disease education, HU management, motivational interviewing, care coordination and social support.
Study: NCT04118166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg, injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation of the tumors occur between investigational agent treatment Cycles 1 and 2, and will be performed according to standard procedures

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg, injection
Study: NCT04013334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTG201
Description: MTG201, 3 x 10E12 vp delivered by intratumoral injection on days 1, 8, 22 and 50

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Nivolumab 480 mg by IV infusion every 4 weeks
Study: NCT03413085

Intervention type: DEVICE
Group type: OTHER
Intervention: soft contact lens
Description: Group A~Group B

Intervention type: DEVICE
Group type: OTHER
Intervention: soft contact lens
Description: Group A~Group B
Study: NCT04041219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), initially administered sublingually for four consecutive doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), oral administration after sublingual four consecutive doses
Study: NCT01880736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
Study: NCT00949897

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofoam
Description: Device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iliac Crest Allograft with locked plate
Study: NCT00468182

Intervention type: DRUG
Intervention: Interferon-beta 1b (Betaseron)
Description: Treatment of patients with FDA-approved Rx
Study: NCT03155529

Intervention type: PROCEDURE
Intervention: radical hysterectomy
Description: A standard radical hysterectomy with lymphadenectomy was performed. Static and dynamic MRI were performed. A suggested urodynamic examination was done according to the ICS. A 3D reconstruction technique was used to construct the 3D model of the pelvis, pelvic floor muscle, pelvic organ such as bladder and urethral.
Study: NCT02814240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fibroscan
Study: NCT04163861

Intervention type: DIAGNOSTIC_TEST
Intervention: 2d speckle tracking echocardiography
Description: 2d speckle tracking echocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: 2d speckle tracking echocardiography
Description: 2d speckle tracking echocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: serum BNP level
Description: serum BNP level of HFpEF study subjects
Study: NCT03724058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trident® II Clusterhole HA Acetabular Shell
Description: Hip arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trident® Hemispherical Acetabular Shell
Description: Hip arthroplasty